Dr. Utsab Debnath
Designation and Department& School:
Total years in experience: Research Experience – 10 years; Post PhD experience – 5 years
Papers published in journals: 19
Papers presented in conferences: 01
Citations: 127 (https://scholar.google.co.in/citations?user=fOGSjYIAAAAJ&hl=en)
Academic Background (Degrees, University Name & Year of Passing):
Pharm – West Bengal University of Technology, 2008
Pharm (Pharmaceutical Chemistry) – West Bengal University of Technology, 2010
D (Pharmaceutical Chemistry) – CSIR- Central Drug Research Institute (Registration from Integral University), 2016
Honours and Achievements:
GPAT Qualified in 2010
CSIR-Direct SRF awarded in 2011
SERB-NPDF awarded in 2017
During PhD work:
Designed and synthesize different thiazolidine-4-one and piperazine basedanalogues as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against HIV-1.
Molecular modelling studies including docking, 3D-QSAR, vHTS, Molecular Dynamics etc. to design newpyridin-2-one and related analogues as NNRTIs.
Designed and synthesize a new scaffold via molecularmodelling to inhibit the activity of integrase
An in-silico exploration for new antimalarials: Arylsulfonyloxy acetimidamides as prospective agents. Apart from my PhD work, I made significant research contributions in other diseases like Leashmania and Cancer.
Designed and synthesis of tubulin and topoisomerase II inhibitors fordeveloping new chemical entities as anti-cancer agents
Investigated new allicin analogues to understand the structure activity relationship (SAR) against caspase-3 enzyme.
Design and synthesis of Aryl quinolinyl hyadrazone derivatives as anti-inflammatory agents that inhibit TLR4 activation in the macrophages.
Conformational perturbation of SARS-CoV-2 spike protein by N-acetyl cysteine (NAC) to get aprobable strategy to combat COVID-19.
Identification of novel targets of infectious diseases and cancer by various in silico methods followed by implementation of newcomputational methods to screen large databases of heterocyclic molecules for the development of new inhibitorsagainst the target enzyme.
Hit to lead formation followed by lead optimization via organic synthesis.
Structure activity relationship (SAR) based on Molecular docking &QSAR method.
Recent Publications: (2015-2020)
Debnath U, Dewaker V, Prabhakar Y. S., Bhattacharyya P, Mandal A. Conformational Perturbation ofSARS-CoV-2 Spike Protein Using N-Acetyl Cysteine, a Molecular Scissor: A Probable Strategy to CombatCOVID-19. ChemRxiv. 2020. Preprint.https://doi.org/10.26434/chemrxiv.12687923.v1
IslamK, PalK,Debnath U, BashaRS, KhanAT, JanaK, MisraAK. Anti-cancer potential of (1, 2-dihydronaphtho [2, 1-b] furan-2-yl) methanone derivatives. Bioorganic & Medicinal Chemistry Letters. 30 (20), 127476.https://doi.org/10.1016/j.bmcl.2020.127476
Mandal SK, Debnath U, Kumar A, Thomas S, Mandal S, Choudhury MD, Palit P. Natural Sesquiterpene Lactones in the Prevention and Treatment of Inflammatory Disorders and cancer: A Systematic Study of this Emerging Therapeutic Approach based on Chemical and Pharmacological Aspect. Letters in Drug Design & Discovery, 17, 2020, pp. 1102-1116(15). https://doi.org/10.2174/1570180817999200421144007
Bhaumik I, Pal K, Debnath U, Jana K, Misra A. K.; Natural product inspired Allicin analogues a novel anticancer agent
Debnath U, Mukherjee S, Joardar N, Jana K, Sinha Babu S.P., Misra A. K.; Aryl quinolinyl hyadrazonederivatives as anti-inflammatory agents that inhibit TLR4 activation in the macrophages. Eur J Pharm. Sci. 2019, 134:102-115.https://doi.org/10.1016/j.ejps.2019.04.016
Kondaparla S*, Debnath U*, Soni A, Dola V, Sinha M, Srivastava K, Puri S, and Katti S. B. Katti;Synthesis, Biological Evaluation and Molecular Modeling Studies of Chiral Chloroquine Analogues asAntimalarial Agents. Antimicrob Agents Chemother. 2018, 62(12): e02347-17 (*equal contribution)DOI: 10.1128/AAC.02347-17
Kamil R. F., Debnath U., Verma S., Prabhakar Y.S.; Identification of adjacent NNRTI binding pocket inmulti-mutated HIV1-RT Enzyme Model, An in-silico study. Curr HIV Res. 2018; 16(2): 121-129.https://doi.org/10.2174/1570162X16666180412165004
Das N, Bhattacharya A, Kumar Mandal S, Debnath U, Dinda B, Mandal S C, Kumar Sinhamahapatra P,Kumar A, Dutta Choudhury M, Maiti S, Palit P. Ichnocarpus frutescens (L.) R. Br. root derived phytosteroids defends inflammation and algesia by pulling down the pro-inflammatory and nociceptivepain mediators: An in-vitro and in-vivo appraisal. Steroids. 2018; (139): 18-27.https://doi.org/10.1016/j.steroids.2018.09.005
Pyne P, Alam M, Rameez MJ, Mandal S, Sar A, Mondal N, Debnath U, Mathew B, Misra A K,MandalAK, Ghosh W; Homologs from sulfur oxidation (Sox) and methanol dehydrogenation (Xox) enzymesystems collaborate to give rise to a novel pathway of chemolithotrophic tetrathionate oxidation. MolMicrobiol. 2018; 109(2): 169-191.
Debnath U, Singh P, Gupta S K, Katti S.B.; N-hydroxy substituted 2-aryl acetamide analogues:new class of integrase inhibitors. Chem Biol Drug Des. 2017; 90(4):527-534.
Deshpande S, Shivahare R, Debnath U, Sane S. A., Srivastava K, Haq W., Puri S. K., Gupta S, Katti S. B.;Synthesis, Antileishmanial and Antiplasmodial Activity of 7-trifluromethyl Substituted 4-Aminoquinoline Derivatives. The natural products journal. 2017, 7(2): 137-143.
Saxena R, Gupta G, Manohar M, Debnath U, Popli P, Prabhakar Y.S., Konwar R, Kumar S, Kumar A,Dwivedi A; Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl)spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53function. Int J Biochem Cell Biol. 2016, 70:105-17.
Kushwaha R N, Debnath U, Singh P, Saxena R, Gupta S K, Tripathi R K, Siddiqui H H, Katti S. B.; NewPiperazine-Derived NNRTIs as Anti-HIV Agent: Synthesis, Biological Evaluation and MolecularDocking Studies. Indo American Journal of Pharm Research, 2015: 5(01).
Debnath U, Verma S, Singh P, Rawat K, Gupta S K, Tripathi R K, Siddiqui H H, Katti S. B., PrabhakarY. S.; Synthesis, Biological Evaluation and Molecular Modeling studies of New 2,3-diheteroarylthiazolidin-4-ones as NNRTIs. Chem Biol Drug Des. 2015. 86(5): 1285-91.https://doi.org/10.1111/cbdd.12591
Verma S, Debnath U, Agarwal P, Srivastava K, Prabhakar Y. S. In Silico Exploration for NewAntimalarials: Arylsulfonyloxy Acetimidamides as Prospective Agents. J Chem Inf Model. 2015,55(8):1708-19.https://doi.org/10.1021/acs.jcim.5b00392
Projects or Ph.D.s guided:Nil
Books Published: 01
Debnath U and Katti S. B.; Recent Developments in HIV-1 Integrase Inhibitors; Advances in Studies onEnzyme inhibitors, Volume 1: Anticancer and Antiviral Drugs; Nova science publishers; NY, USA. 2017Jan, pp 287-312. (ISBN: 978-1-53610-9)(ebook).
Personal interests:Gardening, listen music, Playing cricket